Non-Hodgkin Lymphoma (NHL): Types, Symptoms, Diagnosis, Stages and Treatment (2026 Guide)

Medically reviewed content · Published 2026 · Last reviewed August 2026

Non-Hodgkin lymphoma (NHL) is a broad group of cancers that begin in lymphocytes white blood cells that are part of the immune system. NHL is not one disease; it’s an umbrella term for dozens of distinct lymphomas that differ in the cell they arise from (B-cell, T-cell, or natural killer/NK-cell), how quickly they grow, where in the body they start, and how they respond to treatment.

Some NHL subtypes grow slowly and may be watched rather than treated immediately; others grow rapidly and need urgent, intensive treatment and some of those aggressive forms are actually more curable than the slow-growing ones. Because of this diversity, the exact subtype identified on biopsy not the general label “NHL” — is what actually determines a person’s treatment and outlook.

This guide explains how NHL is classified and diagnosed, what the major subtypes are and how they’re treated differently, current treatment options including chemotherapy, rituximab and other antibody therapies, CAR-T cell therapy, bispecific antibodies, and stem cell transplant, and what NHL treatment and its cost look like for international patients considering care in India. This is general medical education, not a diagnosis or an individual treatment recommendation

Is Non-Hodgkin Lymphoma Cancer?

Yes. Non-Hodgkin lymphoma is cancer, but the term covers a very wide range of outcomes. Some indolent (slow-growing) subtypes can be managed for many years, sometimes decades, more like a chronic condition than an emergency, with periods where no treatment is needed at all. Some aggressive subtypes, including the most common NHL type, diffuse large B-cell lymphoma, are potentially curable with standard treatment in a majority of patients. Others particularly certain relapsed, refractory, or high-grade T-cell lymphomas remain genuinely difficult to treat. There is no single honest answer to “how serious is NHL” without knowing the specific subtype, stage, and individual patient factors.

Non-Hodgkin Lymphoma vs. Hodgkin Lymphoma

Lymphoma is broadly divided into two categories that are diagnosed and treated differently.

NHL is not simply “a more severe version” of Hodgkin lymphoma — they’re different disease categories with different biology, and NHL’s own subtypes vary in aggressiveness more than Hodgkin lymphoma’s do.

Types of Non-Hodgkin Lymphoma

Modern lymphoma classification is based on the cell of origin, how the cells look under the microscope (morphology), the surface markers they express (immunophenotype), and specific genetic features using the WHO fifth edition (WHO-HAEM5, 2022) and the International Consensus Classification (ICC), the two current frameworks pathologists reference, which mostly but not entirely agree with each other.

B-cell lymphomas (the large majority of NHL)

• Diffuse large B-cell lymphoma (DLBCL) — the single most common NHL subtype
• Follicular lymphoma
• Mantle cell lymphoma
• Marginal zone lymphoma
• Burkitt lymphoma
• Primary mediastinal large B-cell lymphoma
• Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) — closely related, sometimes grouped with NHL
• Other, rarer B-cell subtypes

T-cell and NK-cell lymphomas (less common, more heterogeneous)

• Peripheral T-cell lymphoma, not otherwise specified
• Angioimmunoblastic-type / nodal T-follicular helper-cell lymphomas (renamed and reorganized under current WHO/ICC classification)
• Anaplastic large cell lymphoma (ALK-positive and ALK-negative forms behave differently)
• Extranodal NK/T-cell lymphoma, nasal type
• Other, rarer T- and NK-cell subtypes

This isn’t an exhaustive pathology catalogue dozens of rarer subtypes exist. The subtypes above are the ones patients most commonly encounter, and the ones where treatment approach differs meaningfully enough to matter for a general reader.

B-Cell vs. T-Cell vs. NK-Cell Lymphoma

This distinction matters because it changes which treatments even apply. B-cell lymphomas make up roughly 85–90% of NHL cases and are the group where antibody therapies targeting CD20 (like rituximab), CAR-T therapy, and bispecific antibodies are primarily used, since these treatments target markers found on B-cells. T-cell and NK-cell lymphomas are a smaller, more biologically diverse group where these specific B-cell-targeted therapies generally don’t apply, and treatment more often relies on different chemotherapy combinations, and in select cases, different targeted or cellular therapies specific to T-cell disease. A pathology report confirming B-cell, T-cell, or NK-cell origin is one of the first and most treatment-determining pieces of information in an NHL diagnosis.

Aggressive vs. Indolent NHL

This is one of the most important distinctions for understanding what a specific NHL diagnosis actually means.

Indolent lymphomas typically grow slowly, sometimes over years. Examples include follicular lymphoma (in its more common lower-grade forms), many marginal zone lymphomas, and small lymphocytic lymphoma. Indolent doesn’t mean harmless — these lymphomas are still cancer, can progress, and in some cases transform into a more aggressive lymphoma over time. But it does mean that immediate treatment often isn’t necessary, and long-term management, sometimes spanning decades, is realistic for many patients.

Aggressive lymphomas typically grow rapidly and usually need prompt treatment. Examples include DLBCL, Burkitt lymphoma, and several high-grade T-cell lymphomas. “Aggressive” does not mean “untreatable” — quite the opposite in many cases. DLBCL, despite being aggressive, is potentially curable with standard chemoimmunotherapy in a majority of patients, and Burkitt lymphoma, one of the fastest-growing cancers known, is highly curable with intensive treatment when managed urgently at a specialized center. Aggressive lymphomas often carry a better realistic chance of cure than indolent ones — because a fast-growing cancer generally responds more visibly and completely to chemotherapy than a slow-growing one does.

Symptoms of Non-Hodgkin Lymphoma

Symptoms vary by subtype, location, tumor burden, and whether the disease is nodal or extranodal. Commonly reported symptoms include:

• Painless swelling of lymph nodes — neck, armpit, or groin
• Fever without an obvious infection
• Drenching night sweats
• Unexplained weight loss
• Persistent fatigue
• Abdominal swelling or discomfort
• Shortness of breath or chest pressure (if lymph nodes in the chest are involved)
• Recurrent infections
• Easy bruising or bleeding, in select cases involving bone marrow
• Bone pain, in select cases

It’s worth stating plainly: enlarged lymph nodes have many causes, most of them benign (infections being the most common), and do not automatically mean lymphoma. Persistent, painless, progressively enlarging nodes — especially alongside fever, night sweats, or weight loss — warrant medical evaluation, not immediate alarm.

B symptoms

“B symptoms” is a specific clinical term, not just any fever or sweating. It refers to three specific findings used in lymphoma staging and prognosis:

• Unexplained fever (typically defined as above 38°C/100.4°F without infection)
• Drenching night sweats that soak clothing or bedding
• Unintentional weight loss of more than 10% of body weight over six months

Their presence or absence is formally recorded (as “B” or “A” alongside the numeric stage) because it correlates with disease burden and can affect treatment decisions and prognosis. Not every fever or night sweat during a lymphoma workup meets this specific definition.

Extranodal Non-Hodgkin Lymphoma

NHL can start outside lymph nodes entirely — a pattern seen more often in NHL than in Hodgkin lymphoma. Extranodal sites include the gastrointestinal tract (the most common extranodal site), skin, brain (see Primary CNS Lymphoma below), testes, bone, lungs, and liver. Symptoms depend entirely on the organ involved — a gastric lymphoma might cause symptoms resembling an ulcer, while a skin lymphoma presents as a rash or nodule. Importantly, extranodal involvement does not automatically mean advanced or Stage IV disease — a single extranodal site with no other spread can, in specific staging circumstances, still represent limited-stage disease. Staging always depends on the full pattern of involvement, not the presence of extranodal disease alone.

Non-Hodgkin Lymphoma: Causes, Diagnosis, Staging & Treatment

Risk Factors

Most NHL cases have no single identifiable cause. Risk factors may include:

• Older age
• Weakened immune system, including after transplantation
• HIV infection
• Certain autoimmune diseases
• Previous chemotherapy or radiation
• Some environmental or occupational exposures
• Family history in selected cases

Certain infections, including EBV, H. pylori, hepatitis C, and HTLV-1, are linked to specific lymphoma subtypes rather than NHL as a whole.

Diagnosis

Diagnosis usually involves:

1. Medical history and physical examination
2. Blood tests
3. CT, PET/CT, or MRI imaging
4. Lymph node or tissue biopsy
5. Histopathology, immunohistochemistry, and flow cytometry
6. Cytogenetic or molecular testing when needed
7. Bone marrow testing in selected cases
8. Final staging

A biopsy is essential to determine the exact lymphoma subtype. Excisional or incisional biopsy is often preferred because lymphoma classification requires examination of tissue architecture.

Staging

NHL is generally staged using the Lugano classification:

• Stage I: One lymph node region or localized extranodal site
• Stage II: Multiple regions on the same side of the diaphragm
• Stage III: Lymph nodes on both sides of the diaphragm
• Stage IV: Widespread involvement of extranodal organs

Stage IV NHL is not automatically terminal. Many advanced lymphomas respond well to treatment, depending on subtype and biology.

Treatment

Treatment depends on the lymphoma subtype, stage, symptoms, overall health, and molecular findings. Options include:

• Active surveillance for selected indolent lymphomas
• Chemotherapy
• Monoclonal antibodies such as rituximab
• Targeted therapy
• Bispecific antibodies
• CAR-T cell therapy
• Stem cell transplantation
• Radiation therapy
• Supportive and palliative care

R-CHOP remains an important treatment for many DLBCL cases, while other regimens are used for follicular, mantle cell, Burkitt, and T-cell lymphomas.

Advanced & Relapsed NHL

For relapsed or refractory disease, treatment may include CAR-T therapy, bispecific antibodies, targeted drugs, salvage chemotherapy, stem cell transplantation, or clinical trials. The best option depends on the exact subtype and previous treatments.

Prognosis

NHL outcomes vary greatly by subtype. Some aggressive lymphomas, including many DLBCL and Burkitt lymphoma cases, can be cured, while indolent lymphomas may be controlled for many years. Prognosis depends on factors such as stage, age, LDH level, molecular features, overall health, and treatment response.

Non-Hodgkin Lymphoma Treatment Cost in India

There is no single “NHL treatment cost” — total cost depends entirely on subtype, stage, and which combination of treatments a specific patient needs. Below is a component breakdown based on currently published figures, which vary meaningfully by source and hospital.

A specific pricing gap worth flagging directly: India’s domestically developed CAR-T product, NexCAR19, is priced in the ₹30–40 lakh range (roughly $36,000–$48,000) for the domestic and SAARC-region market — but published international-patient pricing for CAR-T therapy in India (across available products) runs $45,000–$85,000. If you see a low CAR-T figure quoted online, confirm directly whether it reflects domestic Indian pricing or the actual quote an international patient will receive — the two are not interchangeable, and the gap can be tens of thousands of dollars. The same caution applies to overall “lymphoma treatment starting from $3,000–$6,000” figures found in research for this piece — these typically reflect a single, limited component (such as a few chemotherapy cycles for early-stage indolent disease) rather than a realistic total for aggressive or relapsed disease requiring transplant or CAR-T.

Why International Patients Consider India for NHL Care, and How to Choose a Center

India has developed substantial capacity in hematologic oncology, including access to modern diagnostics (flow cytometry, FISH, molecular testing), chemotherapy and antibody therapy, radiation oncology, and both autologous and allogeneic stem cell transplantation, alongside a domestically developed and increasingly available CAR-T product. For international patients, the main draw is typically this combination of advanced capability with costs generally lower than the US, UK, or much of Europe — though India shouldn’t be treated as automatically “the best” option for every patient; several countries, including some in Southeast Asia and parts of Europe, also offer mature hematologic oncology and cellular therapy programs, and the right choice depends on an individual patient’s disease, budget, and travel considerations.

When evaluating a center for NHL care in India or anywhere look for:

• A dedicated hematologic oncologist and hematopathologist, not general oncology coverage alone
• In-house flow cytometry, FISH, and molecular diagnostics with reasonable turnaround
• PET/CT access
• Chemotherapy and antibody therapy delivery with appropriate infection-control infrastructure
• CAR-T capability where relevant to your subtype, including ICU-level monitoring for toxicity management
• An established stem cell transplant program (autologous and, if relevant, allogeneic with donor-matching support)
• Radiation oncology
• A multidisciplinary lymphoma tumor board
• Clinical trial access, where relevant
• Established international patient services (visa letters, coordination, interpreter support)

Verify accreditation, named specialist credentials, and specific CAR-T or transplant program capability directly with the hospital, rather than relying solely on third-party “top hospital” listicles, which are common in this space and don’t substitute for independent verification.

The International Patient Treatment Journey

1. Share existing biopsy, pathology, and imaging reports for review
2. Confirm lymphoma subtype with the receiving pathology team (a pathology re-review is common and often recommended for lymphoma specifically, given how much subtype affects treatment)
3. Determine grade/biological behavior (aggressive vs. indolent)
4. Confirm staging
5. Complete molecular/FISH testing where indicated
6. Multidisciplinary specialist opinion
7. Treatment plan developed, with alternatives explained
8. Hospital and specialist confirmation
9. Written, itemized cost estimate
10. Medical visa guidance
11. Travel and accommodation arrangements
12. Begin treatment
13. Monitor response and manage side effects
14. Discharge and recovery planning
15. Remote follow-up and report-sharing with the home-country physician

No credible provider can guarantee a diagnosis, cure, CAR-T eligibility, treatment response, an exact final cost, visa approval, or survival outcome before reviewing a patient’s actual pathology and full clinical picture be cautious of any provider offering these guarantees upfront.

How Shifam Health Helps International NHL Patients

Shifam Health is a medical tourism facilitator, not a hematology department, oncology clinic, pathology laboratory, transplant center, or CAR-T center — we don’t diagnose lymphoma or determine treatment plans. What we do is help international patients navigate the practical side of accessing NHL care in India: coordinating pathology and record review by relevant specialists, helping shortlist hospitals with genuine hematologic oncology and cellular therapy experience relevant to your subtype, obtaining written treatment and cost estimates, assisting with medical visa documentation, arranging airport pickup and accommodation, providing interpreter support where needed, and staying in touch for follow-up communication once you return home.

If you’ve received an NHL diagnosis and you’re trying to understand what treatment in India could realistically look like, share your available reports with our team on WhatsApp or through a quick inquiry form — there’s no obligation, and we typically respond within 24 hours.

Frequently Asked Questions

People Ask Further Questions

Conclusion

Non-Hodgkin lymphoma is not one disease — it’s dozens of distinct cancers grouped under a single name, and the exact subtype, cell of origin, biological behavior, and stage together determine what a specific diagnosis actually means and which treatment approach makes sense. If you or someone you’re caring for has received an NHL diagnosis, understanding these distinctions — and asking direct questions about your own subtype, pathology, and staging — is the most useful step before deciding on a treatment path, in India or anywhere else.

This article is for general medical education and does not replace individualized advice from a qualified hematologic oncologist, hematopathologist, or transplant/cellular therapy specialist. It is not a diagnosis, treatment recommendation, or guarantee of any outcome.